SG11201408163VA - Modified fibronectin fragments or variants and uses thereof - Google Patents
Modified fibronectin fragments or variants and uses thereofInfo
- Publication number
- SG11201408163VA SG11201408163VA SG11201408163VA SG11201408163VA SG11201408163VA SG 11201408163V A SG11201408163V A SG 11201408163VA SG 11201408163V A SG11201408163V A SG 11201408163VA SG 11201408163V A SG11201408163V A SG 11201408163VA SG 11201408163V A SG11201408163V A SG 11201408163VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- taiwan
- street
- june
- title
- Prior art date
Links
- 102000016359 Fibronectins Human genes 0.000 title abstract 2
- 108010067306 Fibronectins Proteins 0.000 title abstract 2
- 239000012634 fragment Substances 0.000 title abstract 2
- 241000286209 Phasianidae Species 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261656671P | 2012-06-07 | 2012-06-07 | |
PCT/US2013/044699 WO2013185027A2 (en) | 2012-06-07 | 2013-06-07 | Modified fibronectin fragments or variants and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201408163VA true SG11201408163VA (en) | 2015-01-29 |
Family
ID=49712865
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201408163VA SG11201408163VA (en) | 2012-06-07 | 2013-06-07 | Modified fibronectin fragments or variants and uses thereof |
Country Status (14)
Country | Link |
---|---|
US (1) | US9969791B2 (es) |
EP (1) | EP2859113A4 (es) |
JP (1) | JP6297543B2 (es) |
KR (1) | KR20150041619A (es) |
CN (1) | CN104968796A (es) |
AU (1) | AU2013271445B2 (es) |
BR (1) | BR112014030716A2 (es) |
CA (1) | CA2876135A1 (es) |
IL (1) | IL236098A0 (es) |
IN (1) | IN2015MN00027A (es) |
MX (1) | MX2014015028A (es) |
SG (1) | SG11201408163VA (es) |
TW (1) | TWI580692B (es) |
WO (1) | WO2013185027A2 (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6297543B2 (ja) * | 2012-06-07 | 2018-03-20 | ナショナル チェン クン ユニバーシティー | 修飾フィブロネクチンフラグメント又はバリアント及びその使用 |
WO2015103643A2 (en) | 2014-01-06 | 2015-07-09 | The General Hospital Corporation | Integrin antagonists |
JP6863976B2 (ja) * | 2015-06-26 | 2021-04-21 | スピベル テクノロジーズ アクティエボラーグ | 環状rgd細胞結合モチーフ及びその使用 |
AU2016340763B2 (en) | 2015-10-23 | 2021-04-22 | Jai Prakash | Integrin binding peptides and uses thereof |
WO2019165017A1 (en) * | 2018-02-23 | 2019-08-29 | The University Of Chicago | Methods and composition involving thermophilic fibronectin type iii (fn3) monobodies |
AU2019318538A1 (en) * | 2018-08-08 | 2021-03-25 | The General Hospital Corporation | Polypeptide integrin antagonists |
CN111285932B (zh) * | 2018-12-10 | 2023-07-11 | 武汉禾元生物科技股份有限公司 | 一种从基因工程水稻种子中分离纯化重组人纤维连接蛋白的方法 |
CN113092772A (zh) * | 2019-12-23 | 2021-07-09 | 首都医科大学附属北京世纪坛医院 | 尿液黏连蛋白亚组sa-2及其多肽片段在过敏性疾病中的应用 |
CN112941081B (zh) * | 2021-04-16 | 2023-04-21 | 广州启点生物科技有限公司 | 一种纤连蛋白突变体及其制备方法与应用 |
US11723955B1 (en) | 2022-05-13 | 2023-08-15 | Allgenesis Biotherapeutics Inc. | VEGFR fusion protein pharmaceutical composition |
TWI836609B (zh) * | 2022-09-16 | 2024-03-21 | 國立成功大學 | 纖維黏蛋白第iii型結構域衍生的蛋白質及其應用 |
CN117298257A (zh) * | 2023-07-14 | 2023-12-29 | 杭州恩和生物科技有限公司 | 人纤连蛋白或其功能片段的用途、筛选方法和试剂盒 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
US5753230A (en) * | 1994-03-18 | 1998-05-19 | The Scripps Research Institute | Methods and compositions useful for inhibition of angiogenesis |
US20050118661A1 (en) * | 2002-01-21 | 2005-06-02 | Helen Mardon | Fibronectin variants and screening methods |
AU2009234338B2 (en) * | 2008-01-18 | 2014-07-24 | Burnham Institute For Medical Research | Methods and compositions related to internalizing RGD peptides |
CA2821715A1 (en) * | 2010-12-14 | 2012-06-21 | University Of Rochester | Chimeric fibronectin matrix mimetics and uses thereof |
JP6297543B2 (ja) * | 2012-06-07 | 2018-03-20 | ナショナル チェン クン ユニバーシティー | 修飾フィブロネクチンフラグメント又はバリアント及びその使用 |
-
2013
- 2013-06-07 JP JP2015516240A patent/JP6297543B2/ja active Active
- 2013-06-07 WO PCT/US2013/044699 patent/WO2013185027A2/en active Application Filing
- 2013-06-07 CA CA2876135A patent/CA2876135A1/en not_active Abandoned
- 2013-06-07 TW TW102120488A patent/TWI580692B/zh active
- 2013-06-07 AU AU2013271445A patent/AU2013271445B2/en not_active Ceased
- 2013-06-07 EP EP13800217.5A patent/EP2859113A4/en not_active Withdrawn
- 2013-06-07 KR KR20157000345A patent/KR20150041619A/ko not_active Application Discontinuation
- 2013-06-07 BR BR112014030716A patent/BR112014030716A2/pt not_active Application Discontinuation
- 2013-06-07 IN IN27MUN2015 patent/IN2015MN00027A/en unknown
- 2013-06-07 US US14/406,215 patent/US9969791B2/en active Active
- 2013-06-07 SG SG11201408163VA patent/SG11201408163VA/en unknown
- 2013-06-07 CN CN201380030284.2A patent/CN104968796A/zh active Pending
- 2013-06-07 MX MX2014015028A patent/MX2014015028A/es unknown
-
2014
- 2014-12-07 IL IL236098A patent/IL236098A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2876135A1 (en) | 2013-12-12 |
BR112014030716A2 (pt) | 2018-06-26 |
TWI580692B (zh) | 2017-05-01 |
AU2013271445B2 (en) | 2016-12-15 |
WO2013185027A2 (en) | 2013-12-12 |
MX2014015028A (es) | 2015-08-06 |
EP2859113A2 (en) | 2015-04-15 |
IN2015MN00027A (es) | 2015-10-16 |
JP6297543B2 (ja) | 2018-03-20 |
IL236098A0 (en) | 2015-01-29 |
JP2015521588A (ja) | 2015-07-30 |
AU2013271445A1 (en) | 2015-01-22 |
EP2859113A4 (en) | 2016-04-13 |
TW201412770A (zh) | 2014-04-01 |
KR20150041619A (ko) | 2015-04-16 |
CN104968796A (zh) | 2015-10-07 |
US9969791B2 (en) | 2018-05-15 |
US20150218251A1 (en) | 2015-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201408163VA (en) | Modified fibronectin fragments or variants and uses thereof | |
SG11201408261UA (en) | Syringe | |
SG11201808014SA (en) | Compositions, devices, and methods for cell separation | |
SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
SG11201809912UA (en) | Hybrid carriers for nucleic acid cargo | |
SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
SG11201407417VA (en) | Encoding and reconstruction of residual data based on support information | |
SG11201406787TA (en) | Rnai-based therapies for cardiomyopathies, muscular dystrophies and laminopathies | |
SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201403106SA (en) | Anti-phf-tau antibodies and their uses | |
SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
SG11201407662WA (en) | Process for the preparation of treprostinil and derivatives thereof | |
SG11201408561YA (en) | Tunable materials | |
SG11201407900WA (en) | Benzo [c] isoxazoloazepine bromodomain inhibitors and uses thereof | |
SG11201408821SA (en) | Selective pi3k delta inhibitors | |
SG11201408385TA (en) | Methods of detecting diseases or conditions | |
SG11201408237YA (en) | Compound as wnt signaling inhibitor, composition, and use thereof | |
SG11201407851RA (en) | Synthesis of pyrrolo [2, 3 - b] pyridines | |
SG11201406903SA (en) | Cell culture compositions and methods for polypeptide production | |
SG11201408810TA (en) | Methods of treating arthritis | |
SG11201407729VA (en) | Methods for drug screen using zebrafish model and the compounds screened thereform | |
SG11201407655TA (en) | Therapeutic uses of fibroblast growth factor 21 proteins | |
SG11201407372UA (en) | Nampt inhibitors |